Marked eosinophilia induced by nafamostat mesilate, an anticoagulant in a hemodialysis patient.
A 61-year-old Japanese female on hemodialysis developed marked eosinophilia induced by nafamostat mesilate as an anticoagulant for hemodialysis. This is the first case of hypereosinophilic syndrome induced by nafamostat mesilate in a hemodialysis patient. The elevated eosinophil counts (51,900/mm3) are the highest for hemodialysis-associated eosinophilia. This eosinophilia was eliminated after cessation of nafamostat mesilate. We confirmed that the cause of this eosinophilia was nafamostat mesilate by using the challenge test.
Nakanishi
K
K
Department of Internal Medicine, Osaka National Hospital, Japan.
Kaneko
T
T
Yano
F
F
Horio
M
M
Kawagoe
H
H
Fujii
M
M
Kashiwai
K
K
D000925:Anticoagulants / Q000009:adverse effects*; D001550:Benzamidines; D004802:Eosinophilia / Q000139:chemically induced*; D005260:Female; D006146:Guanidines / Q000009:adverse effects*; D006801:Humans; D008875:Middle Aged; D006435:Renal Dialysis
D000925:Anticoagulants; D001550:Benzamidines; D006146:Guanidines; C032855:nafamostat